2011 ASH-AMFDP Award Recipient to Study Treatment for Leukemia/Lymphoma

The annual award given to underrepresented minority scholars is given this year to a woman who will be studying treatment options for T-cell leukemia/lymphoma:

"Adrienne Phillips, MD, MPH, has been selected to receive the ASH-AMFDP Award to conduct research on HLTV-1 adult T-cell leukemia/lymphoma. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology (ASH) and the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation. It provides four years of support, including an annual stipend of up to $75,000 and an annual grant of $30,000 to support research activities.

"I was thrilled and honored to be the recipient of the ASH-AMFDP award for 2011," said Dr. Phillips. "This award represents an outstanding career development opportunity for which I am tremendously grateful. The support provided by ASH and AMFDP will give me protected time, funding, and career counseling that will advance my research and support my development as an academic hematologist." "

Read More: http://www.medilexicon.com/medicalnews.php?newsid=213196

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap